ESTRO 2025 - Abstract Book

S4412

Late-breaking abstracts

ESTRO 2025

improved both lrRFS (HR 0.45, 80% CI 0.31-0.65; p=0.005) and ADT-FS (HR 0.60, 80% CI:0.43-0.83, p=0.049). Twenty-seven (28%) of 97 patients in the MDT group had CTCAE grade 2 or worse genitourinary toxicity exceeding baseline compared with 29 (31%) of 93 patients in the ENRT group. Seven (7%) of 97 patients in the MDT group had CTCAE grade 2 or worse gastrointestinal toxicity exceeding baseline compared with 8 (9%) of 93 patients in the ENRT group. Conclusion ENRT almost doubles biochemical relapse free survival and improves pelvic control and metastasis-free survival as compared to MDT for patients with PET-detected oligorecurrent nodal pelvic PCa recurrences.